Congestive Heart Failure
Article reviews techniques for calculating lifetime benefit of HF intervention
Published in Heart Disease Weekly, April 24th, 2005
According to the report from England, "Chronic heart failure is responsible for considerable suffering and mortality throughout the world. Clinical trials have consistently demonstrated the benefits of pharmacological therapies such as angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers. These drugs are often quoted as reducing mortality from heart failure, yet all patients with heart failure deteriorate and most will die because of their disease."
C.J. Malkin and K.S. Channer of the Royal Hallamshire Hospital in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
Source: Heart Disease Weekly (2005-04-24)
More Articles from Heart Disease Weekly
- Cardiology
Abnormal wall motion may be a stimulus for matrix metalloproteinase activation - Cardiology
Determinants of coronary flow are determined by different physiological factors - Cardiology
ECG is the only consistent diagnostic tool for AMI trends over 25 years - Heart Failure
Beta-blocker therapy with bucindolol may attenuate risk of MI in HF patients - Acute Myocardial Infarction
Access-site complications limited after rescue PCI during thrombolysis - Adverse Drug Reaction
Researchers identify possible risk associated with commonly used heart drug - More from this issue of Heart Disease Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
